• Publication Date: 04/01/2008
  • Author(s):
    Blanchard, Evelyne Menzeleev, Ramil Moore, Colleen
  • Organization(s):
    Cirrus Pharmaceuticals, Inc.
  • Article Type: Technical Articles
  • Subjects: Instruments, Product Development/Formulation, Testing, Validation, and Regulatory Compliance
Choosing a testing facility with LC-MSD capability can save significant amounts of time and money for pulmonary delivery product development projects.

According to an estimate produced by the Boston Consulting Group in 2001, development of a new drug cost nearly $900 million, of which more than $150 million was attributable to the chemistry component alone. Given that costs at the time were rising at nearly 7.5% above general price inflation, it’s not unreasonable to guess that chemistry costs are now well above $200 million, and an average of 12 to 17 years elapses between the discovery of a drug and its approval, when it can start generating revenue. For inhalation products, analytical development undoubtedly costs more than for solid dosage and other drug forms due to additional testing necessary for the delivery systems.

Download PDF